In 1992, when Congress created the 340B Drug Pricing Program as a quiet rider on a Veterans Affairs reauthorization, the entire affected drug spend was estimated in the low hundreds of millions of dollars. By 2023, hospitals and clinics participating in the program purchased over $66 billion of medications at the discounted 340B price. The program now consumes a meaningful share of the entire branded pharmaceutical economy. It is also, depending on whom one asks, either the last functioning subsidy for hospitals serving the uninsured or a regulatory loophole large enough to drive a private equity strategy through.
The original premise of 340B was elegant in the way of legislation written quickly and intended to be small. Drug manufacturers participating in Medicaid would be required to extend the same minimum rebate to a defined set of safety-net providers—federally qualified health centers, Ryan White HIV/AIDS clinics, and disproportionate share hospitals serving large populations of low-income patients. The discount was designed to stretch scarce federal resources by allowing covered entities to reach more eligible patients with the savings generated. The phrase ‘covered entity’ has done a great deal of work in the three decades since.
What the statute did not specify, and what subsequent guidance has spent thirty years failing to clarify, is who counts as a patient of a covered entity. A 1996 HRSA guidance offered a definition broad enough to permit, in principle, any patient with a meaningful clinical relationship to the covered entity to qualify. A 2010 ruling permitted contract pharmacies—commercial retail pharmacies under contract with covered entities—to dispense 340B-discounted drugs to those entities’ patients. The contract pharmacy expansion changed the program’s geometry entirely. A small federally qualified health center could now extend its 340B benefit to thousands of patients filling prescriptions at chain pharmacies on the other side of a metropolitan area. By 2024, there were over 32,000 contract pharmacy arrangements in the program, up from a few hundred before the 2010 guidance.
The mechanics of how covered entities monetize the 340B discount are worth describing precisely, because the program’s defenders and critics often talk past one another by glossing over them. A hospital classified as a disproportionate share hospital purchases an oncology drug at the 340B price—typically 25 to 50 percent below the standard wholesale acquisition cost. The hospital then administers or dispenses that drug to a patient whose insurance reimburses at the standard, undiscounted rate. The spread between the 340B acquisition cost and the standard reimbursement is captured by the hospital. There is no statutory requirement that the spread be used to fund services for low-income patients. Some hospitals do precisely that. Others use the margin to expand specialty service lines, purchase oncology practices in affluent suburbs, or contribute to general operating revenue. The Government Accountability Office has noted, in successive reports, that the program lacks any mechanism for tracking whether the discount actually reaches the populations it was designed to serve.
Manufacturer pushback against the contract pharmacy expansion intensified after 2020, when Eli Lilly and several other companies began restricting 340B sales to contract pharmacies, citing concerns about duplicate discounts and inadequate oversight. The restrictions triggered immediate litigation. HRSA issued enforcement letters. The cases worked through the federal courts on conflicting tracks for several years before producing a series of rulings that, in aggregate, sided more with manufacturers than HRSA. The contract pharmacy controversy is now in a strange equilibrium: most large manufacturers have implemented some form of contract pharmacy restriction, covered entities have responded with their own programs to capture eligible discounts through alternative means, and HRSA’s regulatory authority over the dispute remains unsettled.
The political coalition that defends the 340B program is one of the more counterintuitive in healthcare policy. It includes hospital trade associations, which are among the most powerful lobbies in Washington; community health centers, which carry disproportionate moral authority because they serve populations that are politically invisible; rural hospitals, whose continued existence in many congressional districts depends on 340B revenue; and academic medical centers, which use the program’s margin to cross-subsidize teaching, research, and uncompensated care. This coalition is bipartisan in the most reliable sense: no member of either party has any interest in being the first to disrupt it.
The critics of the program are correspondingly diverse and almost entirely outgunned. Pharmaceutical manufacturers oppose the program for obvious reasons, but their opposition is discounted by lawmakers as self-interested. Some health policy researchers, including Rena Conti and Peter Bach in their early NEJM analysis, documented how the program creates incentives for hospitals to expand into communities and patient populations the program was never designed to serve. Independent oncology practices have been progressively absorbed into hospital systems whose 340B status converts the practice’s drug spend into hospital margin overnight. A small number of state legislators, conservative think tanks, and patient advocacy groups concerned about the program’s effects on drug pricing have pressed for reform. None of these constituencies has the institutional weight to move the policy.
What makes the program politically unmovable is that nearly every reform option would visibly hurt hospitals whose operating margins are already thin. The reforms most often proposed—restricting contract pharmacies, narrowing eligibility, requiring reporting on how the savings are used, and imposing a mandatory pass-through to patients—would each reduce the discounts available to covered entities, and the hospitals would respond, accurately, that the lost margin would force closures or service line reductions. Whether this is a good argument depends on whether one believes the hospitals’ alternative use of those funds is providing more value than the manufacturers would provide if the discount were eliminated and the resulting savings flowed elsewhere. The honest answer is that nobody knows, because the program has never been instrumented to produce that comparison.
Several states have moved unilaterally to constrain manufacturer behavior on contract pharmacies. Arkansas passed legislation in 2021 requiring manufacturers to honor contract pharmacy arrangements; Louisiana, Mississippi, and several other states have followed. The constitutional question of whether such state laws are preempted by federal pharmaceutical regulation is now winding through the courts. The Eighth Circuit upheld Arkansas’s law in March 2024, a decision likely to reach the Supreme Court within two years if the circuits split. The doctrinal stakes here are larger than 340B. They concern the boundaries of state regulatory authority over pharmaceutical pricing more broadly, and the ruling, when it comes, will touch policy debates from drug importation to PBM regulation.
There is a quiet question underneath all of this that the program’s defenders have not been forced to answer, and that its critics have not phrased convincingly. If the policy goal is to subsidize healthcare for the underserved, and if a generously funded prescription drug benefit exists for Medicare patients, and if Medicaid covers most of the population the program was designed to serve, what is the actual marginal contribution of 340B in 2026? The answer depends on which covered entities one looks at and what alternative funding mechanisms one assumes. For a federally qualified health center in a poor rural county, the marginal contribution is likely large and difficult to replace. For a major academic medical center expanding its oncology footprint into wealthy suburban markets, the marginal contribution is something else—not nothing, but not what the original 1992 statute appears to have contemplated. The program now functions as both, and reform proposals that fail to distinguish between them tend to founder on the political coalition that benefits from their conflation. The conflation, by this point, is the program.
